

Emmie de Wit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7067753/publications.pdf>

Version: 2024-02-01

111
papers

28,122
citations

30551

56
h-index

25983

112
g-index

135
all docs

135
docs citations

135
times ranked

45381
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances and gaps in SARS-CoV-2 infection models. <i>PLoS Pathogens</i> , 2022, 18, e1010161.	2.1	61
2	Age-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques. <i>Life Science Alliance</i> , 2022, 5, e202101314.	1.3	18
3	Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2. <i>Antiviral Research</i> , 2022, 198, 105246.	1.9	2
4	Antiviral agents for the treatment of COVID-19: Progress and challenges. <i>Cell Reports Medicine</i> , 2022, 3, 100549.	3.3	33
5	Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues. <i>Science Immunology</i> , 2022, 7, eabo0535.	5.6	17
6	Histologic pulmonary lesions of SARS-CoV-2 in 4 nonhuman primate species: An institutional comparative review. <i>Veterinary Pathology</i> , 2022, 59, 673-680.	0.8	19
7	Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion. <i>Journal of Infectious Diseases</i> , 2022, 225, 1118-1123.	1.9	62
8	Evaluation of viral load in patients with Ebola virus disease in Liberia: a retrospective observational study. <i>Lancet Microbe</i> , The, 2022, 3, e533-e542.	3.4	4
9	K18-hACE2 mice develop respiratory disease resembling severe COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009195.	2.1	227
10	Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. <i>Emerging Microbes and Infections</i> , 2021, 10, 1284-1292.	3.0	25
11	Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome. <i>Nature Microbiology</i> , 2021, 6, 1245-1258.	5.9	101
12	Disruption of the Golgi Apparatus and Contribution of the Endoplasmic Reticulum to the SARS-CoV-2 Replication Complex. <i>Viruses</i> , 2021, 13, 1798.	1.5	22
13	Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	146
14	Reston virus causes severe respiratory disease in young domestic pigs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	16
15	Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. <i>Science Advances</i> , 2021, 7, eabj3627.	4.7	24
16	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. <i>Nature Communications</i> , 2021, 12, 5868.	5.8	52
17	A Novel Field-Deployable Method for Sequencing and Analyses of Henipavirus Genomes From Complex Samples on the MinION Platform. <i>Journal of Infectious Diseases</i> , 2020, 221, S383-S388.	1.9	5
18	ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. <i>Nature</i> , 2020, 586, 578-582.	13.7	840

#	ARTICLE	IF	CITATIONS
19	Animal models for COVID-19. <i>Nature</i> , 2020, 586, 509-515.	13.7	705
20	Nipah@20: Lessons Learned from Another Virus with Pandemic Potential. <i>MSphere</i> , 2020, 5, .	1.3	21
21	Next-generation vaccine platforms for COVID-19. <i>Nature Materials</i> , 2020, 19, 810-812.	13.3	276
22	Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. <i>Nature</i> , 2020, 585, 268-272.	13.7	619
23	Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. <i>Nature</i> , 2020, 585, 273-276.	13.7	592
24	Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. <i>Nature Communications</i> , 2020, 11, 4253.	5.8	43
25	Effectiveness of N95 Respirator Decontamination and Reuse against SARS-CoV-2 Virus. <i>Emerging Infectious Diseases</i> , 2020, 26, 2253-2255.	2.0	200
26	Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. <i>Cell</i> , 2020, 183, 1901-1912.e9.	13.5	618
27	Twenty Years of Nipah Virus Research: Where Do We Go From Here?. <i>Journal of Infectious Diseases</i> , 2020, 221, S359-S362.	1.9	15
28	Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. <i>New England Journal of Medicine</i> , 2020, 382, 1564-1567.	13.9	7,369
29	Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6771-6776.	3.3	735
30	The Global Phosphorylation Landscape of SARS-CoV-2 Infection. <i>Cell</i> , 2020, 182, 685-712.e19.	13.5	825
31	A Novel Coronavirus Emerging in China – Key Questions for Impact Assessment. <i>New England Journal of Medicine</i> , 2020, 382, 692-694.	13.9	1,104
32	Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models. <i>JCI Insight</i> , 2020, 5, .	2.3	35
33	Dose-response and transmission: the nexus between reservoir hosts, environment and recipient hosts. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019, 374, 20190016.	1.8	30
34	Onward transmission of viruses: how do viruses emerge to cause epidemics after spillover?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019, 374, 20190017.	1.8	41
35	Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. <i>Antiviral Research</i> , 2019, 163, 70-74.	1.9	8
36	Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	166

#	ARTICLE	IF	CITATIONS
37	Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas. <i>Viruses</i> , 2019, 11, 212.	1.5	75
38	1918 H1N1 Influenza Virus Replicates and Induces Proinflammatory Cytokine Responses in Extrarepiratory Tissues of Ferrets. <i>Journal of Infectious Diseases</i> , 2018, 217, 1237-1246.	1.9	49
39	Transmission of henipaviruses. <i>Current Opinion in Virology</i> , 2018, 28, 7-11.	2.6	41
40	Mini viral RNAs act as innate immune agonists during influenza virus infection. <i>Nature Microbiology</i> , 2018, 3, 1234-1242.	5.9	96
41	The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2107-2113.	1.4	107
42	Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques. <i>Frontiers in Immunology</i> , 2018, 9, 205.	2.2	41
43	Outbreaks in a Rapidly Changing Central Africa " Lessons from Ebola. <i>New England Journal of Medicine</i> , 2018, 379, 1198-1201.	13.9	56
44	Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. <i>Antiviral Research</i> , 2018, 156, 64-71.	1.9	26
45	The Effect of Plasmodium on the Outcome of Ebola Virus Infection in a Mouse Model. <i>Journal of Infectious Diseases</i> , 2018, 218, S434-S437.	1.9	3
46	Sustained fecal-oral human-to-human transmission following a zoonotic event. <i>Current Opinion in Virology</i> , 2017, 22, 1-6.	2.6	46
47	Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. <i>Antiviral Research</i> , 2017, 143, 30-37.	1.9	56
48	Dromedary camels in northern Mali have high seropositivity to MERS-CoV. <i>One Health</i> , 2017, 3, 41-43.	1.5	37
49	Reply to Colebunders. <i>Clinical Infectious Diseases</i> , 2017, 64, 232.2-232.	2.9	0
50	Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. <i>Npj Vaccines</i> , 2017, 2, 28.	2.9	81
51	Domestic Pig Unlikely Reservoir for MERS-CoV. <i>Emerging Infectious Diseases</i> , 2017, 23, 985-988.	2.0	18
52	The Merits of Malaria Diagnostics during an Ebola Virus Disease Outbreak. <i>Emerging Infectious Diseases</i> , 2016, 22, 323-6.	2.0	25
53	Nanopore Sequencing as a Rapidly Deployable Ebola Outbreak Tool. <i>Emerging Infectious Diseases</i> , 2016, 22, 331-4.	2.0	175
54	Identifying Early Target Cells of Nipah Virus Infection in Syrian Hamsters. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005120.	1.3	23

#	ARTICLE	IF	CITATIONS
55	Clinical Chemistry of Patients With Ebola in Monrovia, Liberia. <i>Journal of Infectious Diseases</i> , 2016, 214, S303-S307.	1.9	7
56	Plasmodium Parasitemia Associated With Increased Survival in Ebola Virus-Infected Patients. <i>Clinical Infectious Diseases</i> , 2016, 63, 1026-1033.	2.9	42
57	Replication and shedding of MERS-CoV in Jamaican fruit bats (<i>Artibeus jamaicensis</i>). <i>Scientific Reports</i> , 2016, 6, 21878.	1.6	138
58	Ebola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014-2015. <i>Journal of Infectious Diseases</i> , 2016, 214, S169-S176.	1.9	24
59	SARS and MERS: recent insights into emerging coronaviruses. <i>Nature Reviews Microbiology</i> , 2016, 14, 523-534.	13.6	2,752
60	A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection. <i>Veterinary Pathology</i> , 2016, 53, 521-531.	0.8	27
61	An Acute Immune Response to Middle East Respiratory Syndrome Coronavirus Replication Contributes to Viral Pathogenicity. <i>American Journal of Pathology</i> , 2016, 186, 630-638.	1.9	35
62	Syrian Hamsters (<i>Mesocricetus auratus</i>) Orally Inoculated With a Nipah Virus Isolate From Bangladesh or Malaysia Develop Similar Respiratory Tract Lesions. <i>Veterinary Pathology</i> , 2015, 52, 38-45.	0.8	32
63	Birth and Pathogenesis of Rogue Respiratory Viruses. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2015, 10, 449-471.	9.6	3
64	Identification of Amino Acid Substitutions Supporting Antigenic Change of Influenza A(H1N1)pdm09 Viruses. <i>Journal of Virology</i> , 2015, 89, 3763-3775.	1.5	73
65	Animal models of disease shed light on Nipah virus pathogenesis and transmission. <i>Journal of Pathology</i> , 2015, 235, 196-205.	2.1	58
66	Mutation rate and genotype variation of Ebola virus from Mali case sequences. <i>Science</i> , 2015, 348, 117-119.	6.0	127
67	Safety of Recombinant VSV-Ebola Virus Vaccine Vector in Pigs. <i>Emerging Infectious Diseases</i> , 2015, 21, 702-704.	2.0	27
68	Molecular Evidence of Sexual Transmission of Ebola Virus. <i>New England Journal of Medicine</i> , 2015, 373, 2448-2454.	13.9	380
69	Possible sexual transmission of Ebola virus - Liberia, 2015. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 479-81.	9.0	132
70	Replication and Shedding of MERS-CoV in Upper Respiratory Tract of Inoculated Dromedary Camels. <i>Emerging Infectious Diseases</i> , 2014, 20, 1999-2005.	2.0	233
71	Middle East Respiratory Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia. <i>MBio</i> , 2014, 5, e00884-14.	1.8	359
72	Infection with MERS-CoV Causes Lethal Pneumonia in the Common Marmoset. <i>PLoS Pathogens</i> , 2014, 10, e1004250.	2.1	186

#	ARTICLE	IF	CITATIONS
73	Foodborne Transmission of Nipah Virus in Syrian Hamsters. <i>PLoS Pathogens</i> , 2014, 10, e1004001.	2.1	56
74	Correction to Middle East Respiratory Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia. <i>MBio</i> , 2014, 5, .	1.8	209
75	Influenza Virus A/Anhui/1/2013 (H7N9) Replicates Efficiently in the Upper and Lower Respiratory Tracts of <i>Cynomolgus</i> Macaques. <i>MBio</i> , 2014, 5, .	1.8	23
76	MERS-CoV: the intermediate host identified?. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 827-828.	4.6	16
77	Treatment with interferon- β and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. <i>Nature Medicine</i> , 2013, 19, 1313-1317.	15.2	412
78	Inhibition of novel β coronavirus replication by a combination of interferon- β and ribavirin. <i>Scientific Reports</i> , 2013, 3, 1686.	1.6	250
79	Comparison of the Pathogenicity of Nipah Virus Isolates from Bangladesh and Malaysia in the Syrian Hamster. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2024.	1.3	71
80	Pneumonia from Human Coronavirus in a Macaque Model. <i>New England Journal of Medicine</i> , 2013, 368, 1560-1562.	13.9	126
81	Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16598-16603.	3.3	264
82	The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Does Not Replicate in Syrian Hamsters. <i>PLoS ONE</i> , 2013, 8, e69127.	1.1	114
83	Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route. <i>Scientific Reports</i> , 2012, 2, 736.	1.6	93
84	The immune response to Nipah virus infection. <i>Archives of Virology</i> , 2012, 157, 1635-1641.	0.9	19
85	Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets. <i>Science</i> , 2012, 336, 1534-1541.	6.0	1,416
86	Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies. <i>Genome Medicine</i> , 2011, 3, 5.	3.6	20
87	Insertion of a multibasic cleavage site in the haemagglutinin of human influenza H3N2 virus does not increase pathogenicity in ferrets. <i>Journal of General Virology</i> , 2011, 92, 1410-1415.	1.3	32
88	Assessment of Rodents as Animal Models for Reston Ebolavirus. <i>Journal of Infectious Diseases</i> , 2011, 204, S968-S972.	1.9	22
89	Nipah Virus Transmission in a Hamster Model. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1432.	1.3	55
90	Pandemic 2009 H1N1 Influenza Virus Causes Diffuse Alveolar Damage in <i>Cynomolgus</i> Macaques. <i>Veterinary Pathology</i> , 2010, 47, 1040-1047.	0.8	34

#	ARTICLE	IF	CITATIONS
91	Introduction of Virulence Markers in PB2 of Pandemic Swine-Origin Influenza Virus Does Not Result in Enhanced Virulence or Transmission. <i>Journal of Virology</i> , 2010, 84, 3752-3758.	1.5	126
92	<i>In Vitro</i> Assessment of Attachment Pattern and Replication Efficiency of H5N1 Influenza A Viruses with Altered Receptor Specificity. <i>Journal of Virology</i> , 2010, 84, 6825-6833.	1.5	146
93	Molecular Determinants of Adaptation of Highly Pathogenic Avian Influenza H7N7 Viruses to Efficient Replication in the Human Host. <i>Journal of Virology</i> , 2010, 84, 1597-1606.	1.5	148
94	Insertion of a Multibasic Cleavage Motif into the Hemagglutinin of a Low-Pathogenic Avian Influenza H6N1 Virus Induces a Highly Pathogenic Phenotype. <i>Journal of Virology</i> , 2010, 84, 7953-7960.	1.5	73
95	Severity of Pneumonia Due to New H1N1 Influenza Virus in Ferrets Is Intermediate between That Due to Seasonal H1N1 Virus and Highly Pathogenic Avian Influenza H5N1 Virus. <i>Journal of Infectious Diseases</i> , 2010, 201, 993-999.	1.9	121
96	Seasonal and Pandemic Human Influenza Viruses Attach Better to Human Upper Respiratory Tract Epithelium than Avian Influenza Viruses. <i>American Journal of Pathology</i> , 2010, 176, 1614-1618.	1.9	146
97	Pathogenesis and Transmission of Swine-Origin 2009 A(H1N1) Influenza Virus in Ferrets. <i>Science</i> , 2009, 325, 481-483.	6.0	544
98	Practical Considerations for High-Throughput Influenza A Virus Surveillance Studies of Wild Birds by Use of Molecular Diagnostic Tests. <i>Journal of Clinical Microbiology</i> , 2009, 47, 666-673.	1.8	126
99	Emerging influenza. <i>Journal of Clinical Virology</i> , 2008, 41, 1-6.	1.6	72
100	Pathogenicity of highly pathogenic avian influenza virus in mammals. <i>Vaccine</i> , 2008, 26, D54-D58.	1.7	48
101	The Molecular Basis of the Pathogenicity of the Dutch Highly Pathogenic Human Influenza A H7N7 Viruses. <i>Journal of Infectious Diseases</i> , 2007, 196, 258-265.	1.9	129
102	A reverse-genetics system for Influenza A virus using T7 RNA polymerase. <i>Journal of General Virology</i> , 2007, 88, 1281-1287.	1.3	61
103	Human and Avian Influenza Viruses Target Different Cells in the Lower Respiratory Tract of Humans and Other Mammals. <i>American Journal of Pathology</i> , 2007, 171, 1215-1223.	1.9	473
104	Rapid sequencing of the non-coding regions of influenza A virus. <i>Journal of Virological Methods</i> , 2007, 139, 85-89.	1.0	24
105	Fitness costs limit escape from cytotoxic T lymphocytes by influenza A viruses. <i>Vaccine</i> , 2006, 24, 6594-6596.	1.7	67
106	Evidence for specific packaging of the influenza A virus genome from conditionally defective virus particles lacking a polymerase gene. <i>Vaccine</i> , 2006, 24, 6647-6650.	1.7	29
107	H5N1 Virus Attachment to Lower Respiratory Tract. <i>Science</i> , 2006, 312, 399-399.	6.0	573
108	Protection of Mice against Lethal Infection with Highly Pathogenic H7N7 Influenza A Virus by Using a Recombinant Low-Pathogenicity Vaccine Strain. <i>Journal of Virology</i> , 2005, 79, 12401-12407.	1.5	76

#	ARTICLE	IF	CITATIONS
109	Functional Constraints of Influenza A Virus Epitopes Limit Escape from Cytotoxic T Lymphocytes. Journal of Virology, 2005, 79, 11239-11246.	1.5	89
110	Role of the Pilot Protein YscW in the Biogenesis of the YscC Secretin in Yersinia enterocolitica. Journal of Bacteriology, 2004, 186, 5366-5375.	1.0	80
111	Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Research, 2004, 103, 155-161.	1.1	171